EurekaMag.com logo
+ Site Statistics
References:
53,517,315
Abstracts:
29,339,501
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Studies on the terminal stages of antibody complement mediated killing of a tumor cell part 1 evidence for the existence of an intermediate line 1 hepatoma cells



Studies on the terminal stages of antibody complement mediated killing of a tumor cell part 1 evidence for the existence of an intermediate line 1 hepatoma cells



Journal of Immunology 116(5): 1272-1275



The mechanism of the terminal steps in the lysis of antibody-sensitized tumor cells by complement (TAC) was studied. Once complement reacted, lysis proceeded even in the absence of fluid-phase complement. Transformation of TAC to dead cells was at least a 2-step process; 1 of the steps was temperature dependent, and the other was reversibly inhibited by EDTA. In analogy to the hemolytic system, TAC was designated T* [line-1 guinea pig hepatoma cells].

(PDF 0-2 workdays service: $29.90)

Accession: 006522444

Download citation: RISBibTeXText



Related references

Studies on the terminal stages of antibody-complement-mediated killing of a tumor cell. I. Evidence for the existence of an intermediate, T. Journal of Immunology 116(5): 1272-1275, 1976

Studies on the terminal stages of antibody complement mediated killing of a tumor cell part 2 inhibition of transformation of line 1 hepatoma cells to dead cells by cyclic amp. Journal of Immunology 116(5): 1276-1279, 1976

Studies on the terminal stages of antibody complement mediated killing of a tumor cell part 3 effect of membrane active agents. Journal of Immunology 117(1): 106-109, 1976

Studies on the terminal stages of antibody-complement-mediated killing of a tumor cell. II. Inhibition of transformation of T to dead cells by 3'5' cAMP. Journal of Immunology 116(5): 1276-1279, 1976

Evidence for a tumor cell complex intermediate in the antibody complement mediated killing of tumor cells. Journal of Immunology 116(6): 1729, 1976

Studies on the terminal stages of antibody-complement mediated killing of a tumor cell. III. Effect of membrane active agents. Journal of Immunology 117(1): 106-109, 1976

Complement mediated killing of a tumor cell line is reduced by preincubation of target cells with gamma interferon. FASEB Journal 5(6): A1463, 1991

Complement depletion in vitro limits monoclonal antibody 6-19-dependent complement-mediated killing of tumor cells in bone marrow. Experimental Hematology 19(9): 863-867, 1991

Complement mediated killing of myeloma tumor cells differences in susceptibility to lysis by antibodies and complement are independent of antigen expression and antibody binding. Immunology 49(2): 321-328, 1983

Lysis of tumor cells by antibody and complement part 6 enhanced killing of enzyme pre treated tumor cells. Journal of Immunology 116(3): 661-668, 1976

Inhibition of antibody-complement-mediated killing of tumor cells by hormones. Cancer Research 36(10): 3672-3677, 1976

A rapid alternative to the clonogenic assay for measuring antibody and complement-mediated killing of tumor cells. Clinical Immunology and Immunopathology 34(2): 263-271, 1985

Metabolic requirements for hormone-induced resistance to antibody-complement mediated killing of tumor cells. Journal of Immunology 119(3): 789-794, 1977

The role of complement, antibody, and tumor necrosis factor alpha in the killing of Plasmodium falciparum by the monocytic cell line THP-1. Infection and Immunity 65(12): 5342-5345, 1997

Complement mediated killing of a cell line is reduced by preincubation of target cells with interferons alpha and gamma. Complement & Inflammation 8(3-4): 235-236, 1991